Action CVAC CUREVAC N.V.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués CureVac N.V.

Actions

CVAC

NL0015436031

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 12/09/2024 		Varia. 5j. Varia. 1 janv.
3,090 USD +1,98 % Graphique intraday de CureVac N.V. +8,42 % -26,60 %
12/09 GSK plc annonce les résultats positifs d'un essai de phase II (Nct06431607) pour son programme de vaccin contre la grippe saisonnière à base d'ARNm CI
12/09 Le fabricant britannique GSK fait passer son vaccin antigrippal à l'ARNm au stade des essais cliniques avancés RE

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
EQ
CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
AQ
CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
EQ
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
AQ
CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
AQ
CureVac N : Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) Form 6 K
PU
CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
EQ
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
EQ
CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
EQ
Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer
AQ
CureVac Provides Update on Trial Dates for Patent Litigation across Multiple Geographies against Pfizer, BioNTech
AQ
CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
EQ
CureVac N : .V 6 K (AGM 2024 Tabulation) As Filed 07.09.2024
PU
CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
AQ
GSK and CureVac to restructure collaboration into new licensing agreement | GSK
AQ
CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
EQ
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
EQ
CureVac Announces Voting Results of General Meeting
EQ
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza, Development in Collaboration with GSK
AQ
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK
EQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action CVAC
  4. Actualités CureVac N.V.
  5. Communiqués
-40% Offre à Durée Limitée : Nos abonnements vous guident vers les meilleurs investissements de demain.
PROFITEZ-EN MAINTENANT
Etats-Unis

Zonebourse is also available in this country: United States.

Switch edition
Rester sur l'édition actuelle